Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clesrovimab→

Clesrovimab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2429913-18-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodyMonoclonal antibody / antibody–drug conjugate
Mechanism of action
Fusion Protein Inhibitors [MoA]
Indications / reported uses
  • respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season
  • RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clesrovimab Environmental Risk Assessment (ERA) (the Clesrovimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.